The Increase In Gene Therapies Is Fueling The Growth Of The Market Due To Their Ability To Target Genetic Causes And Slow Disease Progression: An Emerging Driver Transforming The Huntington's Disease Treatment Market Landscape

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Projected Growth of the Huntington's Disease Treatment Market?
The market size for treating Huntington's disease has experienced a quick rate of growth in the past few years. The market is anticipated to expand from $0.73 billion in 2024 to $0.83 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.3%. Several factors have contributed to this historical growth, including heightened awareness about genetic disorders, increased access to genetic testing, enhanced investment in research for neurodegenerative diseases, an increase in clinical trials for new therapies, and a burgeoning pipeline of drugs aimed at modifying the disease.

There is an expectation of significant expansion in the Huntington's disease treatment market in the approaching years. It is predicted that by 2029, the market will accelerate to $1.35 billion, with a compound annual growth rate (CAGR) of 13.0%. The expected growth during this projected term may be owing to an increased emphasis on personalized medicine, rising incorporation of digital health monitoring, expanded regulatory approval for orphan drugs, surged demand for therapies providing symptomatic relief, and escalating requirement for disease-altering treatments. Key market trends for the forecast period encompass technology-supported gene silencing tools, emerging cell-based therapies, growth in peripheral biomarkers, the incorporation of telehealth in Huntington's disease care, patient-reported outcomes integration, and innovations in disease-altering drugs.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24245&type=smp

What Are the Different Huntington's Disease Treatment Market Segments?
The huntington's disease treatment market covered in this report is segmented -

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies
2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical
3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers

Subsegments
1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers
2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp

What Are the Primary Drivers Shaping the Huntington's Disease Treatment Market?
The surge in gene therapies is anticipated to boost the expansion of the Huntington's disease treatment market in the future. Gene therapies entail the alteration or substitution of faulty genes with the goal of treating or averting genetic diseases. These therapies are gaining traction as precision medicine progresses, which allows for the direct targeting of genetic flaws and yielding superior results than standard treatments. In Huntington's disease, gene therapies specifically inhibit the defective HTT gene that produces harmful proteins, thus preventing neuronal damage. This approach contributes to slowing the progression of the disease, safeguarding brain function, and potentially providing long-term control. For example, by the end of Q1 2023, there were 247 gene therapies in phase II as per the American Society of Gene & Cell Therapy (ASGCT) and Citeline, both based in the US. However, this number saw a rise of 5%, reaching 260 by the end of Q2 2023. Hence, the rise in gene therapies is fuelling the expansion of the Huntington's disease treatment market.

Which Companies Are Leading in the Huntington's Disease Treatment Market?
Major companies operating in the huntington's disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., H. Lundbeck A/S, WaVe Life Sciences Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Annexon Inc., Uniqure NV, Sage Therapeutics Inc., Azevan Pharmaceuticals Inc., Prilenia Therapeutics B.V.

What Are the Major Trends Shaping the Huntington's Disease Treatment Market?
Top corporations in the Huntington's disease treatment market are concentrating on creating advanced treatments like selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules. These advanced therapies aim to enhance the quality of life of patients and decelerate disease progression. Selective VMAT2 inhibitor capsules work by blocking the vesicular monoamine transporter 2, a protein pivotal for preparing neurotransmitters for brain release. The function of these medications is to lessen the release of neurotransmitters, assisting in handling involuntary movements and related symptoms. For example, in August 2023, Neurocrine Biosciences, Inc., a biotech firm from the U.S., secured the U.S. Food and Drug Administration's (FDA) approval for Ingrezza (valbenazine) capsules. These capsules are used to treat adult patients suffering from chorea linked with Huntington's disease (HD). The capsules, consumed once daily, are oral VMAT2 inhibitors that function by moderating excessive dopamine signaling in the brain, aiding the control of involuntary movements. Available in several strengths, the medication can be taken with or without meals, providing an accessible mode of dosage for patients.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/huntington's-disease-treatment-global-market-report

What Are the Top Revenue-Generating Geographies in the Huntington's Disease Treatment Market?
North America was the largest region in the Huntington's disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington's disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Huntington's Disease Treatment Market?
2. What is the CAGR expected in the Huntington's Disease Treatment Market?
3. What Are the Key Innovations Transforming the Huntington's Disease Treatment Industry?
4. Which Region Is Leading the Huntington's Disease Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.